Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14
Diabetes should be well-managed before starting therapy Active pituitary tumors: Stimulating a gland with an active tumor is contraindicated Monitoring Requirements Safe use of CJC-1295/Ipamorelin requires ongoing physician monitoring: Baseline labs: IGF-1, fasting glucose, HbA1c, thorough metabolic panel, CBC 4-6 week follow-up: IGF-1 to confirm dose response
Prudent long-term use strategies Cycle rather than use continuously
Zheng et al., 2019)
The compounds are not interchangeable
Sermorelin is a shorter analogue of growth hormone-releasing hormone (GHRH) with a relatively short half-life, whereas CJC-1295 has been modified to extend its activity, particularly the DAC (Drug Affinity Complex) version, which can remain active for much longer
